Ossipow Vincent 4

What Happened

• Vincent Ossipow, a director of SOPHiA GENETICS SA (SOPH), was granted two awards on June 18, 2026: 19,724 restricted stock units (RSUs) and 28,818 derivative awards (options/other contingent rights), each recorded at $5.46 per share. The reported values are $107,693 for the RSUs and $157,346 for the derivative award, for a combined reported value of about $265,039. These are grants/awards (acquisitions) rather than open‑market purchases or sales.

Key Details

• Transaction date: June 18, 2026. Filing date: June 22, 2026 (4 days after the grant).
• Price/value reported: $5.46 per share/unit; totals $107,693 (19,724 RSUs) and $157,346 (28,818 derivative units).
• Shares owned after transaction: Not specified in the filing.
• Footnotes: F1 = RSUs (each RSU represents a contingent right to one ordinary share). F2 = share options (derivative) grant. Both grants vest 100% as of the Issuer’s next scheduled annual meeting of shareholders, subject to Ossipow’s continued service.
• Timeliness: The filing was submitted four days after the grant date; insiders normally must file Form 4 within two business days, so this appears later than the typical filing window.

Context

• These are compensatory awards, not market buys or sales. The RSUs represent a future right to receive shares upon vesting; the derivative award is an option/contingent right that also vests 100% at the next annual meeting (subject to service). Such grants are routine forms of equity compensation and do not by themselves indicate immediate buying or selling of shares.